Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Debt (2022 - 2025)

Historic Total Debt for UroGen Pharma (URGN) over the last 4 years, with Q3 2025 value amounting to $122.1 million.

  • UroGen Pharma's Total Debt rose 33.03% to $122.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 33.03%. This contributed to the annual value of $121.7 million for FY2024, which is 2352.39% up from last year.
  • As of Q3 2025, UroGen Pharma's Total Debt stood at $122.1 million, which was up 33.03% from $122.5 million recorded in Q2 2025.
  • UroGen Pharma's Total Debt's 5-year high stood at $122.5 million during Q2 2025, with a 5-year trough of $70.8 million in Q1 2022.
  • For the 4-year period, UroGen Pharma's Total Debt averaged around $100.7 million, with its median value being $98.3 million (2023).
  • In the last 5 years, UroGen Pharma's Total Debt soared by 3834.06% in 2023 and then plummeted by 49.14% in 2024.
  • UroGen Pharma's Total Debt (Quarter) stood at $97.5 million in 2022, then increased by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024, then grew by 0.31% to $122.1 million in 2025.
  • Its last three reported values are $122.1 million in Q3 2025, $122.5 million for Q2 2025, and $122.1 million during Q1 2025.